Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Instil BioTIL -1.25%31 Debt-to-Equity is 0.77 as of Mar. 2026, which is 83% above its 10-year median of 0.42. GuruFocus rates TIL with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 966 Biotechnology companies, Instil Bio ranks worse than 83.64% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Instil Bio's Debt-to-Equity or its related term are showing as below:
TIL'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.42 Max: 0.77
Current: 0.77
During the past 7 years, the highest Debt-to-Equity Ratio of Instil Bio was 0.77. The lowest was 0.02. And the median was 0.42.
TIL's Debt-to-Equity is ranked worse than 83.64% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs TIL: 0.77
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Instil Bio Debt-to-Equity Related Terms
Instil Bio Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Instil Bio's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TIL vs AURX, MCRB, DWTX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Instil Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instil Bio Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Instil Bio's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Instil Bio's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instil Bio (TIL) has a Debt-to-Equity of 0.77 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Instil Bio and its competitors. This is 83% above median its historical median of 0.42. Over the past decade, Instil Bio's Debt-to-Equity has ranged from 0.02 to 0.77. According to the industry distribution chart, Instil Bio ranks #808 out of 966 companies in the Biotechnology industry, placing it in the top 83.6%.
Is Instil Bio's Debt-to-Equity too high?
Instil Bio's current Debt-to-Equity of 0.77 is 83% above median its 10-year median of 0.42. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.77. The Biotechnology industry median Debt-to-Equity is 0.16. Instil Bio's value of 0.77 is 381.3% above this industry median. Based on the distribution chart, Instil Bio ranks #808 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Instil Bio has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Instil Bio's Debt-to-Equity compare to AURX and MCRB?
According to the Biotechnology industry distribution chart, Instil Bio ranks #808 out of 966 companies for Debt-to-Equity. This places Instil Bio in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Instil Bio's value of 0.77 is 381.3% above this benchmark. Historically, Instil Bio's own Debt-to-Equity has ranged from 0.02 to 0.77 over the past decade. While the company's 10-year median is 0.42 vs. the industry median of 0.16, Instil Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Instil Bio's current Debt-to-Equity of 0.77 is 381.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Instil Bio and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instil Bio's current Debt-to-Equity is 0.77, which is 83% above median its own 10-year median of 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instil Bio stock overvalued right now?
Instil Bio (TIL) has a current Debt-to-Equity of 0.77. The current Debt-to-Equity is 0.77, which is 83% above median its 10-year median of 0.42 and 381.3% above the Biotechnology industry median of 0.16. Instil Bio's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Instil Bio (TIL), the current Debt-to-Equity is 0.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
31GF Score
Get the complete analysis for TIL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TIL has been successfully added to your 
